Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06608927 | Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | PHASE3 | ACTIVE NOT_RECRUITING | 610 | — | — | Dec 13, 2024 | Nov 30, 2030 | Jun 2, 2026 | 111 | United States, Australia +11 |
| Arm | Type | Description |
|---|---|---|
| Arm A (Experimental Arm) | EXPERIMENTAL | Quemliclustat, nab-paclitaxel and gemcitabine will be administered by IV infusion |
| Arm B (Comparator Arm) | PLACEBO_COMPARATOR | Placebo, nab-paclitaxel and gemcitabine will be administered by IV infusion |
| Name | Type | Description |
|---|---|---|
| Quemliclustat | DRUG | Administered as specified in the treatment arm |
| Placebo | DRUG | Administered as specified in the treatment arm |
| Nab-paclitaxel | DRUG | Administered as specified in the treatment arm |
| Gemcitabine | DRUG | Administered as specified in the treatment arm |
Inclusion Criteria: * Have histologically or cytologically confirmed PDAC that is metastatic. * Have not been previously treated for PDAC in the metastatic setting. 1. Prior neoadjuvant and/or adjuvant therapy for PDAC is permitted if completed at least 12 months before randomization. 2. Prior...